FOLH1 and prostate carcinoma: At the 2019 Advanced Prostate Cancer Consensus Conference, more than 50% of panel experts considered referral of patients with no other treatment options for 177Lu-PSMA to be appropriate.184 Since then, two randomised trials, TheraP185,186 and VISION,187 have suggested that 177Lu-PSMA is efficacious and safe in men whose disease has progressed after treatment with enzalutamide or abiraterone and docetaxel.